Posters

Effect of fragmentation of intravitreal dexamethasone implant in patients with macular edema due to branch retinal vein occlusion

Poster Details

First Author: J.Im SOUTH KOREA

Co Author(s):    J. Kim   D. Park                          

Abstract Details



Purpose:

To evaluate the effect of fragmentation of intravitreal dexamethasone implant in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Setting:

Prospective non-randomized cohort study. The study group consisted of all consecutive patients who underwent intravitreal dexamethasone implant for ME due to BRVO between October 2013 and December 2014.

Methods:

Enrolled patients were divided into the single-piece group and multi-piece group by the fragmentation of the dexamethasone implant at postoperative day 1. Slit-lamp biomicroscopy, measurement of best-corrected visual acuity (BCVA), measurement of intraocular pressure (IOP) by applanation tonometry, and central subfield thickness (CST) with spectral-domain optical coherence tomography were performed at baseline and monthly follow-up visit until 6 months.

Results:

Among 68 eyes (68 patients) with dexamethasone implant, 62 eyes (91.2%) showed a single-piece and six eyes (8.8%) showed a multi-piece implant. The number of dexamethasone implant fragments were significantly different between two groups at each follow-up visit (P < 0.001, respectively). Clinical outcomes including BCVA and CST had no significant difference between two groups at each follow-up visit (P > 0.05, respectively). Recurrence of ME occurred in 35 eyes (56.5%) of single-piece group and three eyes (50.0%) of multi-piece group during 6 months, which was not statistically different (P = 0.684). Number of patients with the IOP elevation and cataract progression were not different between two groups (P > 0.05, respectively).

Conclusions:

These results suggest that after intravitreal dexamethasone implant, the single-piece and multi-piece groups did not differ in clinical outcomes during 6 months. In addition, both groups did not differ in the frequency of adverse events significantly.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy